Schubert & Co’s Medpace MEDP Stock Holding History

Schubert & Co’s Portfolio MEDP Stock Details MEDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22	Closed	-$4.14K	–	910
2023 Q1	$4.14K	Sell	22 -2	-8%	-$414	﹤0.01%	535
2022 Q4	$5.1K	Buy	24 +6	+33%	+$1.2K	﹤0.01%	425
2022 Q3	$3K	Buy	18 +4	+29%	+$638	﹤0.01%	636
2022 Q2	$2K	Buy	14 +8	+133%	+$1.16K	﹤0.01%	814
2022 Q1	$1K	Buy	6 +1	+20%	+$165	﹤0.01%	793
2021 Q4	$1K	Buy	+5	New	+$1.05K	﹤0.01%	747

Other funds holding MEDP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schubert & Co's MEDP Position: Q2 2023 in Review

Schubert & Co sold out of Medpace (MEDP) in Q2 2023, closing a stake of 22 shares — an estimated $4.14K sold.

Schubert & Co first reported a position in MEDP in Q4 2021 and held it in 6 quarters. The position peaked at $5.1K in Q4 2022. 464 funds tracked by Wall St. Rank hold MEDP as of Q2 2023.

Schubert & Co reported no remaining Medpace position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 22 Medpace shares in Q2 2023, an estimated $4.14K.
Schubert & Co first reported a position in Medpace in Q4 2021 and held it in 6 quarters.
Schubert & Co's Medpace position peaked at $5.1K in Q4 2022.
464 funds tracked by Wall St. Rank held Medpace as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.